甲泼尼龙联合阿奇霉素治疗儿童支原体肺炎的安全性及疗效分析

目的 分析甲泼尼龙联合阿奇霉素治疗儿童支原体肺炎的安全性及疗效，为临床治疗提供指导。方法 选取2015年12月-2016年12月上海交通大学医学院附属新华医院收治的200例支原体肺炎患儿作为研究对象。随机分为观察组及对照组，每组各100例。两组患儿均接受营养支持、纠正酸碱代谢失衡、吸氧等常规对症处理。对照组患儿在常规治疗基础上接受阿奇霉素静脉滴注治疗，观察组患儿在常规治疗基础上接受甲泼尼龙联合阿奇霉素静脉滴注治疗。7 d为1个疗程，连续治疗3个疗程。比较两组患儿的治疗效果及不良反应发生情况。结果 治疗3疗程后，观察组患儿治疗总有效率显著高于对照组，差异有统计学意义（P<0.05）；观察组患儿肺啰音消失时间、退热时间、咳嗽缓解时间及住院时间等指标均显著优于对照组，差异有统计学意义（P<0.05）。治疗1周后，两组患儿各血清炎症因子水平均较治疗前出现显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组患儿各指标显著低于对照组，差异有统计学意义（P<0.05）。两组患儿总不良反应发生率相比较无显著差异。结论 甲泼尼龙联合阿奇霉素治疗儿童支原体肺炎，可提高治疗效果，快速降低机体炎症反应，安全可靠，临床效果更好。

Safety and efficacy of methylprednisolone combined with azithromycin in children with mycoplasma pneumonia

Objective To observe the safety and efficacy of methylprednisolone combined with azithromycin in children with mycoplasma pneumonia.Methods 200 children with mycoplasma pneumonia December 2015 to December 2016 in our hospital were selected and randomly divided into observation group and control group, 100 cases in each group. Both groups received routine symptomatic treatment. In control group, children were treated with intravenous infusion of azithromycin, in observation group, children received azithromycin combined with methylprednisolone intravenous infusion. The effect were compared.Results After treatment for 3 courses, the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05); the symptoms subsided time and hospitalization time were significantly lower in the observation group than in the control group (P < 0.05); after 1 week of treatment, the levels of serum inflammatory factors in the two groups were significantly lower than those before treatment (P < 0.05), and the degree of decline of the indexes in the observation group was more obvious (P < 0.05); there was no significant difference in the total number of adverse reactions between the two groups.Conclusion Azithromycin combined with methylprednisolone treatment of children with mycoplasma pneumonia, can improve the treatment effect, safe and reliable, worthy of clinical promotion.